Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Advises Use Of Pandemic Flexibilities For Trials In Ukraine

Russian CRO Body Issues Recommendations

Executive Summary

Amid the continuing conflict and the Russian shelling of hospitals in Ukraine, regulatory bodies, health authorities and clinical research organizations are issuing guidance on how to deal with the impact on clinical trials in both Ukraine and Russia.

You may also be interested in...

EMA Explains How To Minimize Trial Disruptions In Face Of Political Conflicts, Natural Disasters

With major disruptions to clinical trials becoming more commonplace due to political conflicts and natural disasters, the European Medicines Agency has developed guidance to help sponsors make risk-based adjustments to manage ongoing studies.

Trial Sponsors Seek New Countries As Russian Market ‘Falls Into The Abyss’

The Russian clinical trials organization ACTO says the “gloomy” prospects for multinational clinical trials in the country have led many sponsors to postpone the initiation of new studies or abandon them entirely in favor of other markets.

Ukraine War Could Spur Changes In The Clinical Trial Paradigm

Decentralized trials are a way to help displaced Ukrainians remain in studies and could encourage greater participation from individuals in other countries, those overseeing sites in Ukraine say.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts